Epicrispr Biotechnologies CEO Amber Salzman, Ph.D. offers up four imperatives for industry leaders working to develop ...

Life sciences organizations face challenges spanning culture, leadership, infrastructure, and skills to implement FAIR data ...

The N=1 frontier isnt just about helping the rarest patients, its about building the infrastructure for medicines future, write experts at Uncommon Cures.

This is Episode 4 of "FDA Fridays," a special series from Cell & Gene: The Podcast, Chief Editor Erin Harris speaks with regulatory affairs expert Daniela Drago, Partner, NDA Partners, about how ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

The number of psychedelic drug developers reaching Phase 2 and Phase 3 clinical trials is growing, in recognition of the level of unmet need in many mental health disorders and other conditions. Those ...

A-Alpha Bio CEO and AlphaSeq platform co-inventor David Younger found himself frustrated by academic science’s seeming tendency to “do science for the sake of science,” which he acknowledges is ...

In the world of biopharmaceutical innovation, groundbreaking scientific discoveries often do not directly translate into commercial success. Simply developing a promising therapeutic based on great ...

Conferences and trade shows are great places to learn about your competitive environment, as most companies in the industry usually attend these events; this includes competitors, suppliers, customers ...

The U.S. Army is a powerhouse of medical research that takes place at multiple facilities worldwide. The mission of Army medical research is to discover, develop, and deploy products that will ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...